A Phase 2B, 8-week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety and Tolerability of the Fatty Acid Amide Hydrolase (FAAH) Inhibitor PF-04457845 in Adults With DSM5 Current Cannabis Use Disorder (CUD)
Latest Information Update: 19 Feb 2024
At a glance
- Drugs JZP 150 (Primary)
- Indications Psychiatric disorders; Substance-related disorders
- Focus Therapeutic Use
- Acronyms FAAH-I MULTI
- 13 Dec 2022 Status changed from recruiting to completed.
- 15 Aug 2019 Planned number of patients changed from 260 to 237.
- 15 Aug 2019 Status changed from active, no longer recruiting to recruiting.